the ncbio biosciences organization — **connections** newsletter

SEPT 2020 UPDATE

Serving the NC Life Sciences Industry

http://ncbioscience.net
919-281-8960

home | about | calendar | news | member benefits | forums | advocacy | contact

NCBIO - Media

Find the latest news from NCBIO on the website ncbioscience.net, on LinkedIn and on Twitter at @ncbio.

NCBIO Links

CED
NCBIO
NC Biotech Center
BRITE
BTEC
BioNetwork
NCBioImpact
North Carolina Pharmaceutical Services Network
NCABR
National Center for Biotechnology Workforce

NCBIO Sustaining Members

Biogen
Lilly
Pfizer
We Work For Health

NCBIO Supporting Members

Cook Medical
Merck
Novartis
VWR

NCBIO This Month

· Legislative Actions in 2020 Discussed During NCBIO Forum
· Rare Pediatric Disease Priority Review Topic of Webinar
· NC Life Science Industry Gets National Attention for COVID-19 Activities
· Register Now for NCBIO Annual Meeting
· NCBIO Supports NC Rulemaking on Newborn Screening
· NCBiotech Awards Nearly $2 Million in Grants, Loans in Latest Quarter
· Participation in Census Important to Economic Growth
· SBIR Week in the Southeast Going Virtual
· NCATS Funding and Other Opportunities Are Available
· CED GRO Application Period Open
· New Members

· At the National Level
· Member News
· Member Benefits
· Calendar

Legislative Actions in 2020 Discussed During NCBIO Forum

The four Co-Chairs of the General Assembly's Life Science Caucus had a lively discussion with NCBIO President Sam Taylor during the NCBIO Legislative Wrap-Up Forum. The legislators emphasized the importance of the economic impact of the industry in North Carolina and its importance in finding treatments and vaccines for COVID-19 during the pandemic. They also discussed budget issues that the State may be facing.

Senator Paul Newton (R-Cabarrus & Union) recognized the importance of life science companies as "innovators and job creators." He outlined some of the budget challenges facing the State, noting a possible revenue shortfall of $2.5B for 2020-2021. He also discussed the importance of delaying the franchise tax for five years to make North Carolina competitive in economic development.

"North Carolina is not just competing with other states but other countries," stated Senator Mike Woodard (D-Durham, Granville & Person). He discussed the importance of government being as nimble as industry in advancing opportunities during the COVID-19 pandemic.

Senator Woodard and Representative Donna McDowell White (R-Johnston) worked together on Senate Bill 315 to clarify the use of nitrogen offset credits generated by water quality improvements in the lower Neuse River Basin. Pending further study by the Department of Environmental Quality, the credits can be used on a one-for-one basis by treatment facilities on inland segments of the River. Representative White noted the importance of this issue to biomanufacturing companies. She also commended the life science industry for the work being done on COVID-19 and for preparing the State for the next virus that occurs.

Representative Robert Reives (D-Chatham & Durham) says lawmakers may be limited in action during the upcoming September 2 special session of the Assembly. He said that until the federal government passes additional COVID-19 measures, there may be little the State can do. He discussed the need for strengthening broadband access across the State particularly to help parents with their children's education.

All of the Co-Chairs emphasized the bipartisan cooperation among Caucus members and the efforts of House and Senate members to collaborate to support the life science industry.

"We appreciate the work these four great legislators are doing in working with the industry on key issues. We are also grateful for the support of all members of the Caucus," said Taylor.

NCBIO thanks BIO, Novo Nordisk, PhRMA and UCB for sponsoring the event.

...

Back to top.

Rare Pediatric Disease Priority Review Topic of Webinar



NCBIO and BIO hosted a panel discussion on the importance of extending the federal Rare Disease Priority Review Voucher Program, which is scheduled to expire September 30th. Congressman G.K. Butterfield (NC-1st), who is sponsoring legislation to extend the program, joined NCBIO President Sam Taylor and three guest panelists to discuss the measure. According to Butterfield, the program has provided "incentives for treatment and cures," that are critical for young children, noting that the voucher program, though valuable to pharmaceutical companies, does not cost taxpayers any money.

Mark Davis, whose young son suffers from the rare disease spinal muscular atrophy (SMA), talked about the positive impact that Biogen's SPINRAZA, a drug designed specifically for SMA, has had on his son's life. Davis said the drug, which did not exist five years ago, is an example of why "companies should continue to be able to participate in this voucher program and develop drugs that improve the lives of children."

"Many drug companies are using cell and gene therapy to develop drugs for rare genetic diseases," said Tara Britt, Founder and President of the Rare Disease Innovations Institute, adding that "North Carolina is fortunate to have a number of companies that are using these technologies to attack rare diseases."

Jamie Gregorian, Senior Director of Federal Government Affairs for BIO, said the program has resulted in the development of 22 new drugs and that lawmakers are interested in passing the reauthorization legislation. He noted, however, that COVID-19 has forced Congress to focus on other areas, and that action will be more likely if members of Congress hear from constituents about the measure's importance.

Back to top.

NC Life Science Industry Gets National Attention for COVID-19 Activities



President Trump tours Fujifilm Diosynth with CEO Martin Meeson.
(Official White House Photo by Shealah Craighead)

North Carolina life science companies are engaged in a variety of endeavors to provide diagnostics, therapeutics and vaccines for the fight against COVID-19. Efforts in the state drew national attention when President Trump toured the Fujifilm Diosynth facility in Morrisville to see the production under way for the vaccine developed by the Maryland company Novavax. Fujifilm Diosynth started production of the first batch of Novavax's NVX-CoV2373 vaccine candidate. More

Two days later Vice President Pence was in the Triangle to meet with Wake Research, which is enrolling volunteers for the Phase III trials of the COVID-19 vaccine developed by Moderna. More

Back to top.

Register Now for NCBIO Annual Meeting

NCBIO's 26th Annual Meeting is being held virtually beginning **Tuesday, September 29 to Friday, October 2 from noon to 1:30 p.m.** Each day, we will host a program session including:

- **Local Election Outlook** with Democratic and Republican campaign consultants discussing the issues that are driving political debate and campaign promises, including an examination of the allure of drug price control and healthcare costs as a political issue.
- **National Policy Outlook and Ramifications** looks at what this means in terms of policy agendas for 2021 and how various issues from the pandemic to the election will impact our members.
- **Value of Life Sciences: The Future of Health for Our People** focuses on the technology landscape in NC in a fireside chat with respected observers of North Carolina's life science landscape interspersed with three TED talks from some of North Carolina's most innovative life science companies.
- **Biotechnology's Promise: Feeding, Fueling and Healing the World** wraps up the week's program of election, policy and promising technologies, and discusses the impact of all on our member companies in terms of job growth and innovation.

To learn more about each topic and session speakers, please check the event page. If you have any questions regarding your registration, please contact Amber Niebauer. Thank you to this year's event sponsors.

- **Platinum:** BIO, Bioventus, Cook Medical, and VWR, Part of Avantor
- **Gold:** Grifols, FUJIFILM Diosynth Biotechnologies, and Merz
- **Silver:** AdvaMed, G1 Therapeutics, GSK, IQVIA Biotech, Liquidia, Mispro Biotech, Nikon, Novo Nordisk, Novozymes, Sage Therapeutics, The Conafay Group, and UCB

Back to top.

NCBIO Supports NC Rulemaking on Newborn Screening

NCBIO President Sam Taylor has sent a letter to the Commission for Public Health and the North Carolina Rules Review Commission in support of *Proposed Rule – 10A NCAC 42B.0102, .0108 and 10A NCAC 43H.0314* (Newborn Screening). The letter stated that NCBIO expresses its strong support for the Rulemaking because it will allow our state to more quickly implement screening programs that meet three important criteria – (1) the presence of a documented medical benefit to the affected infant from early detection and treatment, (2) a reliable screening test for the disorder, and (3) the availability of technology to reliably screen for the disorder.

NCBIO also considers the Rulemaking important because it will allow for screening of every infant regardless of the parents' health insurance status or ability to pay. Screening of this scope is vital since many of the conditions addressed are not immediately evident at birth but can be successfully managed if treated early. Such comprehensive screening is vital if all our State's children are to have a fair and meaningful opportunity to be as healthy as they can be.

Back to top.

NCBiotech Awards Nearly $2 Million in Grants, Loans in Latest Quarter

The North Carolina Biotechnology Center awarded 34 grants and loans totaling nearly $2 million to universities, biosciences companies and other entities in the fourth quarter of its last fiscal year. The awards will support life sciences research, technology commercialization and entrepreneurship throughout North Carolina. More

Back to top.

Participation in Census Important to Economic Growth

NCBIO is recommending that its member companies encourage their employees to participate in the 2020 Census. Currently, the State is lagging in its Census count, with a participation rate of 59.4% compared to a national average of 63.3%. Former Biogen Executive Machelle Sanders, who is now Secretary of the State Department of Administration and Chair of the North Carolina Complete Count Commission, says the State could lose up to $7.4B in federal funds if more people do not participate in the Census.

According to a study by George Washington University, every person counted in the Census results in $1,623 per year in federal funding for North Carolina. In Fiscal Year 2015, the federal government distributed over $16 billion to North Carolina providing resources for schools, health care, highways, and more. To ensure adequate funding for infrastructure and economic growth, North Carolina needs strong participation in the Census.

Data from the Census also determines the number of Representatives North Carolina will send to Congress in the next decade. Based on preliminary data, the State is expected to gain at least one seat.

To learn how Census data impacts you and your community and to participate if you have not yet completed a form, visit 2020census.gov and census.nc.gov.

Back to top.

SBIR Week in the Southeast Going Virtual

The SBIR Week in the Southeast: North Carolina will now be held VIRTUALLY on Monday, September 14th! Don't miss this opportunity to learn from US Small Business Administration's (SBA) Small Business Innovation Research (SBIR) Program Officers and to schedule one-on-one meetings for September 15th, 2020. More details and registration.

Back to top.

NCATS Funding and Other Opportunities Are Available

The National Center for Advancing Translational Sciences (NCATS) invites small businesses and research organizations involved in commercializing innovative medical technologies to apply for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding. More

The FY2021-1 Small Business Innovation Research Contract (SBIR) Program solicitation has been posted! See the full details and download the solicitation from the Grant Engine website.

Back to top.

CED GRO Application Period Open

CED has just introduced, GRO, a **9-week incubator program** that launches **October 5th** and is aimed at high-growth, high-impact companies looking to grow their tech venture through valuable programming and coaching. CED has a proven track record of success in supporting companies through programs like Fast Trac and its sister program Fast Trac Tech Venture.

The application period is open now and will remain open until September 10th. All applications will be reviewed by a selection committee comprised of industry experts.

Back to top.

New Members



The NCBIO Board of Directors approved eight companies as new members of the organization at the July meeting. They are:

Alnylam Pharmaceuticals works to harness the potential of RNAi therapeutics to transform the lives of people living with diseases in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

Cellex Incorporated is a biotechnology company that develops technologies, instruments and assays for testing of human diseases and conditions, particularly at point-of-care (POC) settings.

Data Driven Bioscience provides clinically translatable discovery genomics (DuoSeq), companion diagnostic development and FDA representation to enable the molecular definition of responders and patients at risk for significant adverse events.

Evans General Contractors provides comprehensive design/build and general contracting services to a wide variety of public and private corporations, institutions and commercial developers.

HITT Contracting is a nationally ranked general contractor providing lifecycle construction services from very small to very large projects.

Lab Safety Specialists provide OSHA and EPA compliance for start-up to midsize laboratories. Services include: OSHA plans, online safety training, contract safety services and more.

Sterling Pharma Solutions USA is a full-service CDMO offering expert knowledge and technical agility to offer API development and cGMP contract manufacturing capabilities.

StrideBio, Inc. is a gene therapy company focused on creating and developing its novel adeno-associated viral (AAV) vector engineering (STRIVE) platform "for use in innovative genetic medicines with life-changing or curative potential for patients with devastating conditions, including monogenic rare disease and beyond."

Back to top.

At the National Level

Proposed Executive Order on Drug Pricing Draws Strong Opposition

NCBIO is working with BIO, PhRMA, and national partners to warn about the impact of a potential Presidential Executive Order on drug pricing. "Proposals to pin American drug prices to those paid in foreign countries with government-run health care systems are an abdication of our government's responsibility to find a wholistic American solution to high consumer drug prices," said NCBIO President Sam Taylor. 'Moreover, North Carolina – as one of America's top pharmaceutical manufacturing states – will be disproportionately impacted by the proposal under consideration by the President."

Dr. Michelle McMurry-Heath, President and CEO of BIO, stated in a release, "All across the country, there are scientists and researchers in our labs working day and night to end the COVID-19 pandemic. They are trying desperately to develop the scientific solutions we need to eradicate this devastating public health crisis. We will not overcome this pandemic or future ones if we seek short-sighted policies that adopt foreign price controls from systems that don't value innovation, disrupt providers' ability to deliver care, and increase barriers to patient access. There is a reason that over half of all the science and drug development related to COVID-19 is coming from the U.S." More

In response to the orders, PhRMA President and CEO Stephen J. Ubl said, "In his 2020 State of the Union Address, President Trump declared that 'we will never let socialism destroy American health care.' Yet, in the middle of a global pandemic, when nearly 145,000 Americans have lost their lives and millions of others have suffered untold economic hardships, this administration has decided to pursue a radical and dangerous policy to set prices based on rates paid in countries that he has labeled as socialist, which will harm patients today and into the future." More

NCBIO will continue to work with its national sister organizations to oppose international reference pricing proposals.

President Trump also signed a "Buy American" order related to the manufacturing of pharmaceuticals in the United States. Steve Ubl of PhRMA stated, "The recent executive orders contradict and undermine each other, creating chaos in an industry that is on the frontlines of fighting COVID-19. With the 'Buy American' executive order, the administration effectively is taking the unprecedented step of mandating manufacturing of medicines in the United States. Yet at the same time, through the 'most favored nation' executive order, the administration is creating a huge disincentive to invest in US biopharmaceutical research and manufacturing. Together, the result is less investment in US innovation and the potential for major long-term supply chain disruptions – the opposite of what America needs right now. None of these executive orders will help patients access or afford their medicines." More

Shipments of COVID-19 Molecular Diagnostic Tests Reach 100 Million

The Advanced Medical Technology Association (AdvaMed) announced that total US shipments of COVID-19 molecular diagnostic tests reached approximately 100 million, as of July 25, based on the latest data from the association's national testing registry.

"The 100-million mark represents yet another extraordinary milestone as the medical technology industry ramps up to meet the demand for testing posed by the coronavirus pandemic," said AdvaMed President and CEO Scott Whitaker. "The diagnostics industry will continue to work around the clock, to ensure widespread availability of test kits and supplies, doing everything possible to help beat this public health crisis." More

BIO Announces New Economic Equity Program

BIO announced BIOEquality Agenda which aims to attack the systemic inequality, injustice and unfair treatment of women and communities of color through the positive force of biotechnology. Recognizing that gains from transformative science are not always shared equally, BIO is challenging the industry, and its partners, to find solutions for inequitable healthcare delivery, disparate economic development and nutritional and environmental disparities in the US and around the globe. More

IGNITE American Innovation Act

AdvaMed, BIO, and MDMA are among a coalition of advocates for the startup ecosystem to voice strong support for the *IGNITE American Innovation Act*, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated through a focus on researching and producing products and technologies that create long-term value. The legislation is by far the most significant proposal under consideration to provide liquidity to startups and sustain critical economic activity that will pay long-term dividends to American workers and the economy. More

Sign Up Now for BIO Impact Conference September 21-22

At BIO IMPACT Digital, the focus is on bringing together the global agriculture and environment community to share critical industry insights, form valuable partnerships, and spotlight new innovations making our world more resilient.

Biotechnology can play a key role in pulling society out of the COVID-19 crisis and positioning economies to withstand similar crises in the future. Hear insights on what is needed to grow and secure a resilient bioeconomy, focusing on how innovative technologies and industries can work alongside government to promote needed investments and to create sustainable supply chains for the future. This and more topics during the two-day event.

Register now to join the conversation and for first access to 1,000+ global thought-leaders, critical education, networking, and business partnering to drive your business development through 2020.

The Virtual MedTech Conference October 5-7

The format may have changed, but the commitment to quality has not. The Virtual MedTech Conference covers timely topics and features world-class speakers from the industry and beyond, all in a dynamic and immersive virtual format.

Several panel discussions will be part of a mix of live and on-demand content. One session will focus on business development and will cover the important role that compliance plays in business development due diligence, acquisition, integration, and divestiture activities for companies of all sizes, as well as the benefits of embedding compliance in business development teams and processes.

- **Moderator: Alicia H. Maltz, JD, CCEP, CHPC**, Director, Health Care Compliance Officer - Business Development, Johnson & Johnson
- **John Kilcoyne**, Chief Executive Officer, JenaValve
- **James R. Wilson**, General Manager, Wright Medical Technology Co. (Canada)
- **Matthew Wetzel, JD**, Associate General Counsel & Compliance Officer, GRAIL

Register now through the partnership registration. NCBIO members get a 10% discount. Contact Amber Niebauer to get the code.

BIO Investor Forum October 13-15

BIO is now accepting applications for company presentations at BIO Investor Forum Digital, October 13-15, with more than 130 investors already registered.

Registration rates have been reduced to $790 for BIO members/ $995 for non-members when you reserve a company presentation (includes registration for one person). BIO has already approved 50 companies for the 160 planned presentation slots, so act now and submit the brief application to request your slot. Click to apply.

Presenters benefit from registration that includes access to BIO One-on-One Partnering™, a new audience networking platform and Q&A opportunities will supplement on-demand hosting of company presentations for 30 days. For questions, please contact Emily Longvall at elongvall@bio.org.

Symposium on Rare Cancer Registries

Project Data Sphere (PDS) has teamed up with the FDA to present the FDA - PDS Symposium IX Rare Cancer Registries virtual event. It will be held October 7, Noon-3pm EDT. Rare cancer registries hold potential to solve some of the most difficult challenges to advancing treatment of these rare cancers, which account for more than 20% of the cancers reported worldwide.

The symposium will bring together multiple stakeholders representing all sides of this challenge: practice in the clinic, pharmaceutical research, policy and regulatory science, and patient advocacy to brainstorm the operational dynamics between the groups. Register

Back to top.

Member News

To be included in Member News, send information about your organization to Brenda Summers.

AskBio Co-Founder Jude Samulski has been named one of PharmaVOICE magazine's 100 most inspirational leaders of 2020. Samulski is widely regarded for his work in gene therapy, also founded Bamboo Therapeutics, which was sold to Pfizer in 2016. More

BD (Becton, Dickinson and Company) announced a $24 million investment from the US Department of Defense in collaboration with the US Department of Health and Human Services to support the scale up of US manufacturing capabilities for BD Veritor™ Solution for Rapid Detection of SARS-CoV-2. More

Biogen and Eisai, Co., Ltd. announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer's disease. The application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date on March 7, 2021, and the FDA has stated that, if possible, it plans to act early on this application under an expedited review. More

Boragen, Inc., a boron-based discovery platform company based in the Research Triangle Park, has won a $300,500 Phase I Small Business Innovation Research grant for research on controlling malaria. More

Bristol Myers Squibb and the Bristol Myers Squibb Foundation announced today a combined investment of $300M as part of a series of commitments that are designed to address health disparities, increase clinical trial diversity and for Bristol Myers Squibb to increase the company's spend with diverse suppliers and continue to increase Black/African American and Hispanic/Latino representation at all levels of the company. More

G1 Therapeutics, Inc., a clinical-stage oncology company, announced that the FDA has accepted the New Drug Application (NDA) for trilaciclib for small cell lung cancer (SCLC) patients being treated with chemotherapy and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of February 15, 2021. More

Grifols announced it has delivered the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials. Since April, Grifols has moved quickly to collect COVID-19 convalescent plasma for its anti-SARS-CoV-2 hyperimmune globulin in more than 245 Grifols US donation centers from donors who have met the highest eligibility criteria. Their plasma, rigorously tested and quality controlled, had high levels of anti-SARS-CoV-2 neutralizing antibodies. More

Heat Biologics reports its COVID-19 vaccine demonstrated robust T Cell driven immune response to SARS-CoV-2 in Preclinical Studies. More

The IQVIA™ Institute for Human Data Science released a report on *Medicine Spending and Affordability in the US: Understanding Patient Costs for Medicines.* According to the report, the vast majority of patients in the United States are experiencing lower out-of-pocket costs for their drugs, paying a smaller share of costs and seeing a downward trend in their costs on average. More

Kriya Therapeutics announced that it has secured a 51,350 square foot operational manufacturing facility in Research Triangle Park (RTP), North Carolina to support the scalable production of its pipeline of AAV-based gene therapies for highly prevalent serious diseases. More

Merz Therapeutics announced that the FDA has approved a supplemental Biologics License Application (sBLA) for the first pediatric indication for XEOMIN (incobotulinumtoxinA), for the treatment of patients aged 2 years and older with upper limb spasticity, excluding spasticity caused by cerebral palsy. More

PPD announced it has signed a new three-year agreement with Pfizer Inc. to provide drug development services to advance Pfizer's portfolio. Under the terms of the agreement, Pfizer has the right to extend the term for additional two-year periods. Financial details of the agreement were not disclosed. More PPD announced that two PPD senior leaders have been named to the 2020 PharmaVOICE 100 list of the most inspiring people in the life sciences industry: Karen Kaucic, M.D., chief medical officer of PPD and president of Evidera, and Rhonda Henry, vice president of patient-centered trials.

RTI International has named Amy Helwig as executive vice president of commercial health at RTI International. "The combination of Amy's commercial and government experience makes her uniquely qualified to lead RTI's commercial health practice," said President E. Wayne Holden. More

Seqirus has begun shipping its portfolio of seasonal influenza vaccines to customers in the US for the 2020/21 influenza season. Seqirus is one of the world's largest influenza vaccine companies and is well-positioned to supply up to 60 million doses for the US market this year, depending on demand. More

Smith Anderson received one of the 2020 Best Places to Work from Triangle Business Journal. Smith Anderson was a winner in the Large Company category – those that employ 100 to 249 workers. More

Back to top.

BIO Business Solutions

In 2019, BIO saved 4,300 companies nearly $430 million through BIO Business Solutions® with volume-based discounts and favorable contract terms on lab supplies, waste removal, microscopes, shipping, gases, and more.

NCBIO members, you are eligible for BIO Business Solutions® volume-based discounts and favorable contract terms on lab supplies, waste removal, microscopes, shipping, gases, and more. This is a benefit of your NCBIO membership. Review the cost-savings offered by clicking here and choose the programs you're interested in. Email Bob Dearth or call 781-716-7555 with your choices, and he will get you started. For all the latest news, promos, and event information, follow BIO Business Solutions® on LinkedIn!

BREX Corporate Card

As an NCBIO member, you receive savings and other benefits from our many Preferred Purchasing Program partners including **Brex, the Corporate Card for Life Sciences,** and **just for signing up with Brex you receive 60,000 points** ($600 value when taken as a statement credit) which **helps cover your NCBIO membership fee**! In addition, **you receive 3x points on every purchase of lab supplies,** which is the equivalent of getting another 3% discount on top of the great discounts you already receive from another NCBIO partner - VWR.

Brex empowers its life sciences customers to spend less time on end of month closes and more time on life changing R&D and is **commonly used by young companies for capital preservation and cash management**. Other Brex benefits include:

- **No personal guarantee** (and no credit check)
- **Rewards tailored specifically for Life Science companies** (conference registrations, travel, lab supplies, Apple products)
- **Higher credit limits** than traditional cards
- **Seamless integration with various accounting systems** including QuickBooks
- **Waived card fees for life and no foreign transaction fees**

Click for more information.

UPS Health

The COVID-19 pandemic has presented new challenges for healthcare companies. BIO Business Solutions is proud to partner with UPS Healthcare, who has been helping customers moving critical and temperature-controlled pharmaceuticals, providing lab logistics support for testing and partnering with government agencies to move personal protective equipment (PPE) to pandemic hot spots.

Click for more information.

Back to top.

Calendar

To view full calendar, click.

HOW MANUFACTURERS CAN NAVIGATE RECESSION IN AN INDUSTRY 4.0 WORLD
Thursday Aug 27, 2020
... read more

NC SBIR/STTR Road Tour
Tuesday Sep 8, 2020
... read more

Three I's & Biosecurity™ Conference
Monday Sep 14, 2020 - Wednesday Sep 16, 2020
... read more

NC SBIR/STTR Road Tour
Monday Sep 14, 2020
... read more

NCBiotech Ag Tech Professional Forum
Wednesday Sep 16, 2020
... read more

IntraHealth International SwitchPoint 2020
Thursday Sep 17, 2020 - Friday Sep 18, 2020
... read more

MIRA: Machine-Learning & Informatics Research in Aging
Friday Sep 18, 2020
... read more

2020 BIO IMPACT Ag & Environment Conference
Monday Sep 21, 2020 - Tuesday Sep 22, 2020
... read more

Tech Transfer During Critical Times
Thursday Sep 24, 2020
... read more

NCBIO Annual Meeting 2020
Tuesday Sep 29, 2020 - Friday Oct 2, 2020
... read more

Optimizing Commercial Pharma Channels During COVID-19
Wednesday Sep 30, 2020
... read more

The Virtual MedTech Conference
Monday Oct 5, 2020 - Wednesday Oct 7, 2020
... read more

BTEC Short Courses: Hands-On Single Use Processing for Biopharmaceuticals
Tuesday Oct 6, 2020 - Thursday Oct 8, 2020
... read more

FDA - PDS Symposium IX Rare Cancer Registries
Wednesday Oct 7, 2020
... read more

BIO Investor Forum Digital
Tuesday Oct 13, 2020 - Thursday Oct 15, 2020
... read more

BTEC Short Courses: Hands-On cGMP Biomanufacturing Operations
Tuesday Oct 13, 2020 - Friday Oct 16, 2020
... read more

North Carolina Biosciences Organization © Copyright 2020

email: bsummers@ncbioscience.net phone: 919-281-8960 web: http://ncbioscience.net

NCBIO
P.O. Box 14354
Research Triangle Park
North Carolina 27709